Retifanlimab-dlwr is approved by FDA for metastatic or recurrent locally advanced Merkel cell carcinoma

Merkel cell carcinoma treatment
Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cell cancer (MCC).

Share This Post

April 2023: Retifanlimab-dlwr (Zynyz, Incyte Corporation) received fast approval from the Food and Drug Administration to treat adult patients with metastatic or recurrent locally advanced Merkel cell cancer (MCC).

In PODIUM-201 (NCT03599713), an open-label, multiregional, single-arm study examining 65 patients with metastatic or recurrent locally advanced MCC who had not previously received systemic therapy for advanced illness, safety and efficacy were assessed.

Objective response rate (ORR) and duration of response (DOR), as determined by an independent central review committee in accordance with RECIST v1.1, were the key efficacy outcome measures. The ORR was 52% (95% CI: 40, 65), and 18% of respondents gave their full consent. 26 patients (76%) and 21 (62%), respectively, had DORs of less than six and twelve months.

The 105 MCC patients who made up the safety population. Fatigue, musculoskeletal pain, pruritus, diarrhoea, rash, pyrexia, and nausea were the most frequent side effects (10%). When patients received retifanlimab-dlwr, 22% of them experienced serious side effects.

The dosage of retifanlimab-dlwr that is advised is 500 mg given intravenously over the course of 30 minutes every 4 weeks until the condition progresses, there is intolerable toxicity, or up to 24 months have passed.

View full prescribing information for Zynyz.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer
Endometrial cancer

Durvalumab with chemotherapy is approved by the USFDA for mismatch repair deficient primary advanced or recurrent endometrial cancer

The USFDA has approved Durvalumab combined with chemotherapy for treating mismatch repair-deficient primary advanced or recurrent endometrial cancer. This approval is based on clinical trials demonstrating significant efficacy in this patient group. Durvalumab, an immune checkpoint inhibitor, enhances the immune system’s ability to fight cancer, providing a new therapeutic option and hope for improved survival and quality of life in these challenging cases.

Repotrectinib has received accelerated approval for adult and pediatric patients with NTRK gene fusion-positive solid tumors
Cancer

Repotrectinib has received accelerated approval for adult and pediatric patients with NTRK gene fusion-positive solid tumors

Repotrectinib has received accelerated approval for treating adult and pediatric patients with NTRK gene fusion-positive solid tumors. This approval, based on promising clinical trial results, provides a new therapeutic option for individuals with this specific genetic alteration, offering hope for improved outcomes. The decision underscores the potential of targeted therapies in addressing rare and difficult-to-treat cancers, emphasizing precision medicine’s role in modern oncology.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy